Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000413789 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Captopril Challenge Test Predicts Cardiac Structure and Dysfunction in Primary Aldosteronism.
J Clin Endocrinol Metab
January 2025
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Context: The captopril challenge test (CCT) is a commonly used confirmation test that identifies the magnitude of renin- and angiotensin II-independent aldosterone production, and thus the presence and severity of primary aldosteronism (PA).
Objective: This study investigated the association between the post-CCT plasma aldosterone concentration (PAC) and cardiovascular remodeling and diastolic dysfunction.
Methods: A total of 540 PA patients with complete CCT and echocardiographic data were retrospectively analyzed.
Impact of confirmatory test results on subtype classification and biochemical outcome following unilateral adrenalectomy in patients with primary aldosteronism.
Front Endocrinol (Lausanne)
December 2024
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
Context: Primary aldosteronism (PA) is the most common form of endocrine hypertension. According to the Endocrine Society Practice Guidelines, the diagnosis of PA requires a pathological screening test result and non-suppressible aldosterone levels during confirmatory testing. Sequential testing with more than one confirmatory test may result in discordant test results.
View Article and Find Full Text PDFTarget organ damage in primary aldosteronism and captopril challenge test.
Hypertens Res
November 2024
Department of Nephrology & Hypertension/Blood Purification Center, Dokkyo Medical University, Mibu, Japan.
An In Situ Sustained-Release Chitosan Hydrogel to Attenuate Renal Fibrosis by Retaining Klotho Expression.
Biomater Res
October 2024
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.
Klotho (KLO) is an anti-fibrotic protein expressed in the kidneys and has been decreasing in the development of renal fibrosis (RF). However, restoring the decline in KLO levels remains a great challenge during RF treatment. Herein, an injectable KLO-loaded chitosan (CS) hydrogel (KLO-Gel) is designed to achieve localized and prolonged release of KLO in the RF treatment.
View Article and Find Full Text PDFDifferences in target organ damage between captopril challenge test-defined definitive-positive and borderline-range groups among patients with primary aldosteronism.
Hypertens Res
October 2024
Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Article Synopsis
- The new Japanese guidelines for primary aldosteronism introduce a "borderline range" for functional confirmatory tests, which is not commonly found in other international guidelines.
- This study compared patients in the borderline group to definitive-positive and negative groups using data from a nationwide Japanese registry, analyzing results from 1,785 individuals based on their captopril-challenge test results.
- The findings showed that the borderline group did not differ significantly from the negative group concerning target organ damage, though both groups had higher odds of chronic kidney disease and electrocardiographic abnormalities when compared to definitive-positive patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!